Tuan Zea Tan
Overview
Explore the profile of Tuan Zea Tan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
3742
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teo J, Chauhan A, Nossier R, Tan T, Nga V
Chin Clin Oncol
. 2025 Mar;
14(1):4.
PMID: 40081385
Background: Melanoma stands out as a prevalent instigator of leptomeningeal disease (LMD) within the realm of cancer. Given the poor prognosis accompanying this condition, ongoing trials are exploring a spectrum...
2.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):6.
PMID: 39806516
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote...
3.
Ogasawara A, Matsushita H, Tan T, Shintani D, Ye J, Nagao S, et al.
Gynecol Oncol
. 2024 Oct;
191:124-131.
PMID: 39413557
Background: The iPocc trial, a randomized, global phase 3 study that compared intraperitoneal (IP) and intravenous (IV) carboplatin with dose-dense paclitaxel chemotherapy in epithelial ovarian cancer (EOC) patients, demonstrated improved...
4.
Xiong S, Zhou J, Tan T, Chung T, Tan T, Toh S, et al.
Nat Commun
. 2024 Aug;
15(1):6810.
PMID: 39122682
Multiple myeloma is a hematological malignancy arising from immunoglobulin-secreting plasma cells. It remains poorly understood how chromatin rewiring of regulatory elements contributes to tumorigenesis and therapy resistance in myeloma. Here...
5.
Ong K, Mok M, Niibori-Nambu A, Du L, Yanagida M, Wang C, et al.
Exp Hematol
. 2024 Jun;
137:104255.
PMID: 38876252
The genetic lesions that drive acute megakaryoblastic leukemia (AMKL) have not been fully elucidated. To search for genetic alterations in AMKL, we performed targeted deep sequencing in 34 AMKL patient...
6.
Kong L, Gupta K, Wu A, Perera D, Ivanyi-Nagy R, Ahmed S, et al.
Cell
. 2024 Apr;
187(9):2269-2287.e16.
PMID: 38608703
Knudson's "two-hit" paradigm posits that carcinogenesis requires inactivation of both copies of an autosomal tumor suppressor gene. Here, we report that the glycolytic metabolite methylglyoxal (MGO) transiently bypasses Knudson's paradigm...
7.
Wijaya S, Ngoi N, Loh J, Tan T, Lim D, Khan I, et al.
J Gynecol Oncol
. 2024 Apr;
35(5):e69.
PMID: 38606821
Objective: Ovarian clear cell carcinoma (OCCC) is associated with chemoresistance. Limited data exists regarding the efficacy of targeted therapies such as immune checkpoint inhibitors (ICI) and bevacizumab, and the role...
8.
Lai X, Lui S, Lam H, Adachi Y, Sim W, Vasilevski N, et al.
NPJ Precis Oncol
. 2023 Dec;
7(1):136.
PMID: 38102334
Despite the promising antitumor activity of SHP2 inhibitors in RAS-dependent tumours, overall responses have been limited by their narrow therapeutic window. Like with all MAPK pathway inhibitors, this is likely...
9.
Bou Malham V, Benzoubir N, Vaquero J, Desterke C, Agnetti J, Song P, et al.
Liver Int
. 2023 Oct;
43(12):2776-2793.
PMID: 37804055
Background & Aims: The class I- phosphatidylinositol-3 kinases (PI3Ks) signalling is dysregulated in almost all human cancers whereas the isoform-specific roles remain poorly investigated. We reported that the isoform δ...
10.
Yeo X, Sundararajan V, Wu Z, Phua Z, Ho Y, Peh K, et al.
Commun Biol
. 2023 Jul;
6(1):759.
PMID: 37474650
No abstract available.